{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:56:01Z","timestamp":1775062561117,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>This review is designed to highlight recent research efforts to optimize treatment strategies in men with advanced prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>In hopes of improving outcomes in men with advanced prostate cancer, recent trials have focused on intensifying therapy earlier in the disease course both in men with biochemical recurrence and those with oligometastatic disease. Further research efforts have looked to refine the use of radiopharmaceuticals, targeted therapy, and combinations of existing agents. Finally, systemic therapies with novel targets may expand options for men with treatment-refractory metastatic castration-resistant disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Ongoing research focuses on maximizing the benefits of existing therapies while exploring treatments with new mechanisms of action.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cco.0000000000001237","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:03:59Z","timestamp":1775055839000},"page":"243-248","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Steady progress in the treatment of advanced prostate cancer: a year in review"],"prefix":"10.1097","volume":"38","author":[{"given":"Theodore","family":"Gourdin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"R1-20260401","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the Phase III ARASENS Trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"R3-20260401","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the Randomized Phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"R4-20260401","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open- label, randomised, phase 3 study with a 2\u200a\u00d7\u200a2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"R6-20260401","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"R7-20260401","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R8-20260401","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"R9-20260401","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer","author":"Shore","year":"2025","journal-title":"N Engl J Med"},{"key":"R10-20260401","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.24.00279","article-title":"Metastasis- free survival versus treatment-free survival in biochemically recurrent prostate cancer: the EMBARK Trial","volume":"42","author":"Einstein","year":"2024","journal-title":"J Clin Oncol"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.3390\/cancers15215234","article-title":"Oligometastatic disease (OMD): the classification and practical review of prospective trials","volume":"15","author":"Izmailov","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R12-20260401","doi-asserted-by":"crossref","first-page":"e2452971","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA New Open"},{"key":"R13-20260401","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE Trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"R14-20260401","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1470-2045(25)00351-1","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open- label, randomised, phase 2 trial","volume":"26","author":"Niazi","year":"2025","journal-title":"Lancet Oncol"},{"key":"R15-20260401","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"R16-20260401","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u200a\u00d7\u200a2 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"R17-20260401","article-title":"Impact of prostate radiotherapy on survival outcomes in patients with metastatic castration- sensitive prostate cancer: a meta-analysis of randomized phase 3 clinical trials","volume":"2025","author":"Yazgan","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"R18-20260401","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium- 177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R19-20260401","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"Lu- PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with Progressive Metastatic Castration-Resistant Prostate Cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"R20-20260401","first-page":"1319","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of the 177Lu -PSMA- 617 versus change of androgen receptor pathway inhibitor in taxane-na\u00efve patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"[Ann Oncol"},{"key":"R21-20260401","doi-asserted-by":"crossref","first-page":"oyaf358","DOI":"10.1093\/oncolo\/oyaf358","article-title":"Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617","volume":"30","author":"Panian","year":"2025","journal-title":"Oncologist"},{"key":"R22-20260401","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.eururo.2024.08.021","article-title":"Association of declining prostate-specific antigen levels with clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"key":"R23-20260401","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential 177Lu -PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone sensitive prostate cancer (UpFrontPSMA): a muticentre, pen-lable, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"R24-20260401","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11864-025-01317-5","article-title":"PSMA-based therapies and novel therapies in advanced prostate cancer: the now and the future","volume":"26","author":"Ayzman","year":"2025","journal-title":"Curr Treat Options Oncol"},{"key":"R25-20260401","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"R26-20260401","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"R27-20260401","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"R28-20260401","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the Phase 3 MAGNITUDE Trial","volume":"8","author":"Chi","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"R29-20260401","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"R30-20260401","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration- resistant prostate cancer: a living interactive systematic review and meta-analysis","volume":"87","author":"Naqvi","year":"2025","journal-title":"Eur Urol"},{"key":"R31-20260401","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"R32-20260401","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11523-025-01139-3","article-title":"Safety and tolerability of relugolix in combination with abiraterone or apalutamide for treatment of patients with advanced prostate cancer: data from a 52-week clinical trial","volume":"20","author":"De La Cerda","year":"2025","journal-title":"Target Oncol"},{"key":"R33-20260401","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"key":"R34-20260401","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: a phase I study","volume":"43","author":"Stein","year":"2025","journal-title":"J Clin Oncol"},{"key":"R35-20260401","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/jcph.70074","article-title":"Clinical pharmacology characterization and dose selection of xaluritamig, a next generation XmAb\u00ae 2\u200a+\u200a1 T-cell engager, in prostate cancer patients","volume":"65","author":"Kuipers-Connarn","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"R36-20260401","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00345-025-06075-5","article-title":"Bispecific antibodies in metastatic castration-resistant prostate cancer: therapeutic strategies and frontier advances","volume":"43","author":"He","year":"2025","journal-title":"World J Urol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000001237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:04:03Z","timestamp":1775055843000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000001237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000001237","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}